UNSPSC 51281807: Amrubicin

This classification denotes an anthracycline antibiotic with the molecular formula C25H25NO9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 93N13LB4Z2, chemically known as ( -)-(7s,9s)-9-acetyl-9-amino-7-((2-deoxy-beta-d-erythro-pentopyranosyl)oxy)-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione but generally known as amrubicin, which bears US NIH Compound Identifier 178149. Amrubicin most often comes in base and hydrochloride forms.

UNSPSC 51281807 Amrubicin is a Commodity code that nominally covers a specific chemotherapy agent, but the recent state and local opportunities tagged under it reflect broader pharmaceutical procurement — specifically emergency-response and public-health medications sourced through piggyback contracts and competitive bidding rather than amrubicin itself. State and local health departments and county public-health agencies are the primary issuing bodies, acquiring medications and medical countermeasures through established consortiums or direct procurement to support emergency preparedness, community health, and clinical supply chains. The work involves warehousing, logistics coordination, and supply-chain management as much as the pharmaceutical commodity itself, with vendors responsible for packaging, expiration-dating compliance, quarterly or on-call delivery, and insurance and regulatory certification.

Recent activity spans Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 (completed award, not an open solicitation) for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets over a 12-month initial term with two renewal options. Seminole County, Florida issued an IFB in June 2026 for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the county community health building, a two-year initial term, and a one-year renewal option; the response deadline was July 26, 2023. The code shows limited recent activity and a mismatch between its nominal scope (amrubicin) and the actual pharmaceutical products being procured (antibiotics, opioid antagonists, and deactivation systems), suggesting either misclassification in the source data or use of the code as a catchall for pharmaceutical procurement under state and local health-department vehicles.